Subscribe To
Tarsus to host webcast to review topline results from saturn-2 phase 3, the second pivotal trial of tp-03 for the treatment of demodex blepharitis
IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply pro...
April 29, 2022, 9:23 pm
Ocuphire pharma to present at wet amd & dme drug development summit in boston, ma
FARMINGTON HILLS, Mich., April 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ...
April 6, 2022, 8:00 am
Allergan shares topline data for twice daily vuity (pilocarpine) in blurry vision study
Allergan, an AbbVie Inc (NYSE: ABBV) company, announced topline data from Phase 3 VIRGO trial evaluating Vuity (pilocarpine HCl ...
April 5, 2022, 2:45 pm
Ocuphire pharma to present at oppenheimer annual healthcare conference
FARMINGTON HILLS, Mich., March 10, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ...
March 10, 2022, 9:27 am
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm
Annexon biosciences to present preclinical data supporting complement inhibitor programs for the treatment of guillain-barré syndrome and huntington's disease at aan 2022
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developi...
March 3, 2022, 4:01 pm
Skye bioscience reports positive results for sb-100 in glp toxicology study; phase i clinical trial expected in 2q 2022
Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ...
February 16, 2022, 9:19 am
Skye bioscience reports positive results for sb-100 in glp toxicology study; phase i clinical trial expected in 2q 2022
Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ...
February 16, 2022, 9:19 am
Skye bioscience reports positive results for sb-100 in glp toxicology study; phase i clinical trial expected in 2q 2022
Skye Bioscience inc (OTCQB:SKYE) announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100 ...
February 16, 2022, 9:19 am
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, deve...
October 11, 2021, 12:30 pm